- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Medicus Pharma to present phase 2 data at Biotech Showcase 2026 | 1 | Investing.com | ||
| Mo | Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates | 1 | GlobeNewswire (USA) | ||
| 30.12.25 | Medicus Pharma startet "At-the-Market"-Eigenkapitalprogramm über bis zu 15,3 Mio. US-Dollar | 1 | Investing.com Deutsch | ||
| 30.12.25 | Medicus Pharma Ltd. - 8-K, Current Report | - | SEC Filings | ||
| MEDICUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 22.12.25 | Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence Driven Clinical Data Analytics Platform | 446 | ACCESS Newswire | The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute urinary... ► Artikel lesen | |
| 17.12.25 | Medicus Pharma completes patient enrolment for basal cell carcinoma trial | 1 | PMLiVE | ||
| 15.12.25 | Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin | 149 | GlobeNewswire (Europe) | THE COMPANY EXPECTS TO RELEASE TOPLINE RESULTS FOR SKNJCT-003 PHASE 2 CLINICAL TRIAL BEFORE THE END OF Q1 2026 AND REQUEST END-OF-PHASE 2 (EOP2) WITH THE FOOD AND DRUG ADMINISTRATION (FDA) IN H1 2026... ► Artikel lesen | |
| 08.12.25 | Medicus Pharma Ltd. - 8-K, Current Report | - | SEC Filings | ||
| 05.12.25 | Medicus Pharma sichert sich 5,1 Mio. US-Dollar durch Optionsschein-Vereinbarung | 2 | Investing.com Deutsch | ||
| 05.12.25 | Medicus Pharma secures $5.1 million from warrant exercise agreement | 1 | Investing.com | ||
| 05.12.25 | Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement | 357 | ACCESS Newswire | Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction PHILADELPHIA, PA / ACCESS Newswire / December 5, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company")... ► Artikel lesen | |
| 01.12.25 | Medicus Pharma Appoints President Carolyn Bonner CFO | 3 | RTTNews | ||
| 01.12.25 | Medicus Pharma appoints Carolyn Bonner as CFO after Quinlan resigns | 1 | Investing.com | ||
| 01.12.25 | Medicus Pharma appoints Carolyn Bonner as president and CFO | 1 | Investing.com | ||
| 01.12.25 | Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President | 240 | ACCESS Newswire | Carolyn Bonner Succeeds James ('Jim') Quinlan Who Has Resigned for Health Reasons After Taking Medical Leave in September 2025 PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / December 1, 2025 / Medicus... ► Artikel lesen | |
| 01.12.25 | Doppelrolle bei Medicus Pharma: Carolyn Bonner wird Präsidentin und CFO | - | Investing.com Deutsch | ||
| 01.12.25 | Medicus Pharma ernennt Präsidentin Carolyn Bonner zur neuen Finanzchefin | - | Investing.com Deutsch | ||
| 01.12.25 | Medicus Pharma Ltd. - 8-K, Current Report | - | SEC Filings | ||
| 24.11.25 | Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers | 1 | GlobeNewswire (USA) | ||
| 19.11.25 | Medicus Pharma Ltd. - S-1, General form for registration of securities | - | SEC Filings |
1 2 3 4 Weiter >>
75 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,800 | +1,56 % | EILMELDUNG: Pfizer legt kräftig zu - jetzt reden alle über diesen Wert! | ||
| GILEAD SCIENCES | 104,02 | +3,09 % | Gilead agrees on affordable medicines plan with US government | ||
| ELI LILLY | 909,90 | +2,47 % | Kampf um Adipositas-Markt: Preisoffensive in China: Jetzt reagieren Novo Nordisk und Eli Lilly! | © Foto: Jens Kalaene - picture alliance/dpaNovo Nordisk und Eli Lilly senken in China die Preise für ihre Blockbuster gegen Fettleibigkeit drastisch. Dahinter steckt ein Markt mit gigantischem Wachstum.Novo... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 400,85 | +4,72 % | A Look Into Vertex Pharmaceuticals Inc's Price Over Earnings | ||
| EYEPOINT | 14,410 | -3,03 % | EyePoint Pharmaceuticals, Inc.: EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration | - No changes in protocol recommended for LUGANO and LUCIA clinical trials - - Masked safety data continues to show no safety signals, consistent with previous clinical trials for DURAVYU - - On track... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 12,940 | +0,86 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile | - Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio - - Solidifies double digit growth trajectory for HAE... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 164,00 | +1,23 % | Ligand Pharmaceuticals: Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients | Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled approved product JUPITER, Fla.... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 141,20 | -5,08 % | Jazz Pharmaceuticals stock rating reiterated at Outperform by RBC Capital | ||
| OPKO HEALTH | 1,120 | +2,98 % | OPKO Health Bets on RAYALDEE and Pipeline Progress for 2026 Growth | ||
| UNITED THERAPEUTICS | 411,30 | -1,53 % | United Therapeutics Corporation to Present at Upcoming Investor Conferences | United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions... ► Artikel lesen | |
| ROYALTY PHARMA | 34,670 | +2,51 % | Royalty Pharma Acquires Remaining Evrysdi Royalties From PTC Therapeutics | SOUTH SAN FRANCISCO (dpa-AFX) - Royalty Pharma plc (RPRX) announced that it has acquired the final portion of PTC Therapeutics' remaining royalty interest in Roche's Evrysdi. The transaction... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 19,200 | -1,29 % | Catalyst Pharmaceuticals, Inc.: The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS) | ||
| BRIDGEBIO PHARMA | 62,70 | +0,10 % | Morgan Stanley initiates BridgeBio Pharma stock with Overweight rating | ||
| TG THERAPEUTICS | 25,540 | +0,16 % | TG Therapeutics, Inc.: TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI | NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated... ► Artikel lesen | |
| AVADEL PHARMACEUTICALS | 18,200 | -1,09 % | BlackRock legt 6,72-prozentige Beteiligung an Avadel Pharmaceuticals offen |
Das Unternehmen MEDICUS PHARMA LTD kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,570 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICUS PHARMA LTD finden Sie auf Wallstreet Online.